Simple Endoscopy Score News Today

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult...

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

Head-to-head study compared risankizumab (Skyrizi) to ustekinumab (Stelara) in patients with moderately to severely active Crohn disease.

Mesoblast Prepares for Resubmission of Biologics License Application...

Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn’s and Colitis Organisation (ECCO)...